A meta-analysis by Farmakis et al. demonstrated that PAH-targeted therapies (monotherapy with an ERA or PDE5 inhibitor) improved significantly mPAP, PVR and 6MWD in patients with group 3 PH [110]. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.